PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Beijing Med-Pharm Corporation (Nasdaq: BJGP) announced today that it has entered into a master services agreement with Cephalon, Inc. (Nasdaq: CEPH) under which Beijing Med-Pharm will complete the clinical development and registration process for certain Cephalon products in the People’s Republic of China.
